HDAC9 and acute myeloid leukemia: And HDAC inhibitors, as a series of compounds that neutralize the activities of HDACs, have long been utilized in treatment of AML for pre-clinical studies, which have some extend shown beneficial outcomes (26, 27, 30, 31).